Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorBalta, Cenk
dc.contributor.authorKuzucuoğlu, Mustafa
dc.contributor.authorAslan, Figen
dc.contributor.authorYekdes, Ali Cem
dc.date.accessioned2023-12-28T11:38:19Z
dc.date.available2023-12-28T11:38:19Z
dc.date.issued2022en_US
dc.identifier.issn1309-9469
dc.identifier.urihttps://doi.org/10.5472/marumj.1191101
dc.identifier.urihttps://hdl.handle.net/20.500.12462/13711
dc.descriptionYekdeş, Ali Cem (Balikesir Author)en_US
dc.description.abstractObjective: This study aims to evaluate the efficiencies and effects of different sclerosing agents. Materials and Methods: Thirty-five female Wistar-albino rats were included in this study and divided into five groups randomly. Isotonic saline (group 1), iodopovidone (group 2), rifamycin (group 3), autologous blood (group 4), talc (group 5) were given into intrapleural space. On postoperative 28th day, ipsilateral and contralateral pleural and parenchymal fibrosis and inflammation were evaluated. Results: There were statistically differences between control and other groups on macroscopically pleural fibrosis examination (p=0.004, p=0.001, p=0.001, p=0.000, respectively). Microscopically pleural fibrosis were determined in all groups when compared to control group (p=0.023, p=0.023, p=0.035, p=0.001, respectively). There were no significant differences between sclerosing agent groups (p>0.05). Significant differences were observed according to microscopic pleural inflammation evaluation between talc group and other groups. There was superiority in talc group according to intraparenchymal inflammation grade compared to other groups (p=0.010, p=0.042, p=0.030, respectively). Macroscopically, fibrosis and microscopically, inflammation were significantly observed between talc and other groups in the contralateral pleura (p=0.037and p=0.009, respectively). Conclusion: lodopovidonc, autologous blood, talc, and rifamycin can be used as effective pleurodesis agents. However, we found that rifamycin and autologous blood are safer as effective pleurodesis agents. We think that these two agents can be used in patients with secondary lung diseases due to their less intraparenchymal inflammation rates. It may be advantageous to prefer other sclerosing agents which has lower costs and less side effects comparing to talc.en_US
dc.language.isoengen_US
dc.publisherMarmara Univen_US
dc.relation.isversionof10.5472/marumj.1191101en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPleurodesisen_US
dc.subjectPleural Effusionsen_US
dc.subjectPleural Inflammationen_US
dc.subjectAnimal Experimentsen_US
dc.titleEvaluation of the efficacy of several sclerosing agents for pleurodesis in ratsen_US
dc.typearticleen_US
dc.relation.journalMarmara Medical Journalen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0000-0002-4073-8101en_US
dc.contributor.authorID0000-0001-9889-0061en_US
dc.contributor.authorID0000-0002-8928-2053en_US
dc.identifier.volume35en_US
dc.identifier.issue3en_US
dc.identifier.startpage297en_US
dc.identifier.endpage302en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster